The executive committee of Johnson & Johnson is the principal management group responsible for the strategic operations and allocation of the resources of the company, overseeing and coordinating the activities of the consumer health, pharmaceutical, and medtech business segments. The competitive environment requires substantial investments in continuing research, as the development of new and innovative products, as well as protecting the underlying intellectual property of the company's product portfolio, is important to the company's success in all areas of its business. Leveraging the extensive resources across the enterprise enables the company to innovate and execute with excellence, ensuring the company can remain focused on addressing the unmet needs of society every day and invest for an enduring impact. The company is committed to creating value by developing accessible, high-quality, innovative products and services, with new products introduced within the past five years accounting for approximately 25% of 2022 sales. Research and development activities represent a significant part of the company's business, relating to the processes of discovering, testing, and developing new products, improving existing products, as well as ensuring product efficacy and regulatory compliance prior to launch. The company remains committed to investing in research and development with the aim of delivering high quality and innovative products. The company has achieved approximately $0.8 billion in annual pre-tax cost savings as outlined in the restructuring actions, which included expanding its use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities, and optimize its supply chain network. The company continues to evaluate and monitor both its internal and external supply arrangements, including the impact of external influences on operational flexibility and market response. The company's policy updates regarding customer delivery locations and contract pharmacy transactions are intended to improve its ability to identify inappropriate duplicate discounts and diversion prohibited by the 340B statute, which reflects the company’s commitment to compliance and operational efficiency. The company also invests in both fixed-rate and floating-rate interest-earning securities, managing the impact of foreign exchange rate changes on cash flows through forward foreign exchange contracts and currency swap contracts. The company has a policy of only entering into contracts with parties that have at least an investment-grade credit rating, ensuring a low risk of loss. The company’s strategic management practices include monitoring the global capital markets and raising capital when market conditions are favorable, which supports its operational needs and investment processes. The company's commitment to leveraging its IT capabilities in combination with other resources underscores the importance of mobilizing and deploying IT-based resources to support business needs and transform the firm into a competitive force. The company’s IT infrastructure and governance are critical in ensuring that it can respond to shifting market dynamics and consumer demands, enhancing its organizational capabilities and effectiveness in delivering business value.